Therapy Areas: Oncology
Biocon Biologics wins U.S. FDA approval for interchangeable denosumab biosimilars Bosaya and Aukelso
17 September 2025 - Biosimilars company Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE: 532523) (NSE: BIOCON), announced on Wednesday that it has secured U.S. Food and Drug Administration...
AstraZeneca's Fasenra misses primary endpoint in Phase III COPD trial
17 September 2025 - Biopharmaceutical company AstraZeneca plc (LSE: AZN) (STO: AZN) (Nasdaq: AZN) reported on Wednesday that its Phase III RESOLUTE trial of Fasenra (benralizumab) in chronic obstructi...
LakeShore Biopharma receives Nasdaq delisting determination letter
15 September 2025 - LakeShore Biopharma Co, Ltd (Nasdaq: LSB), a China-based global biopharmaceutical company that is involved in discovering, developing, manufacturing, and delivering new generations...
Citius Oncology closes USD9m registered direct offering and concurrent private placement
11 September 2025 - Citius Oncology Inc (Nasdaq:CTOR), the oncology-focused subsidiary of biopharmaceutical company Citius Pharmaceuticals Inc (Nasdaq:CTXR), announced on Wednesday the closing of its ...
Atossa Therapeutics seeks Type C meeting with FDA to accelerate development of low-dose (Z)-endoxifen for breast cancer risk reduction
9 September 2025 - US-based biotechnology company Atossa Therapeutics Inc (Nasdaq:ATOS) announced on Monday that it has requested a Type C meeting with the US Food and Drug Administration (FDA) to dis...
Phanes Therapeutics reports first BTC patient dosed in trial of spevatamig in combination with chemotherapy
9 September 2025 - Phanes Therapeutics Inc, a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced on Monday that the first patient has been dosed...